AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25

AbbVie Inc.

2023-FY EPS reported $2.72 revenue$54,318,000,000

Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).
Q4 2023 GAAP EPS $0.46 (-66.7%); adjusted EPS $2.79 (-22.5%); revenue $14.3B (-5.4%).
Humira Q4 revenue $3.3B (-40.8% on biosimilar competition); Skyrizi up 51.9%; Rinvoq up 62.9%.
Announced ImmunoGen acquisition (~$10.1B equity) and Cerevel (~$8.7B); expected close mid-2024.
FY2024 adj. EPS guidance $11.05-$11.25 includes $0.32 dilution from pending deals; long-term CAGR reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbbVie Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $14.301 billion, EPS $2.79. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $14.301 billion
EPS: $2.79
Guidance: reaffirmed
Result: reported results

Exact text from the filing

These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense • Delivers Fourth-Quarter Net Revenues of $14.301 Billion, a Decrease of 5.4 Percent • Announced Definitive Transaction Agreements to Acquire ImmunoGen and Cerevel Therapeutics, Strengthening AbbVie’s Oncology and Neuroscience

View on SEC.gov

Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.